1. Home
  2. ORKA

as of 06-15-2026 4:00pm EST

$68.86
$1.03
-1.47%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Founded: 2004 Country:
United States
United States
Employees: N/A City: MENLO PARK
Market Cap: 1.6B IPO Year: N/A
Target Price: $92.50 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $10.97 - $91.00 Next Earning Date: 05-13-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: